Förderung
BMBF DZIF 8055808921 „Manufacture and phase I clinical trial of HY-133, a recombinant phage lysin for rapid decolonization of Staphylococcus aureus from nasal habitats (Herstellung und klinische Phase I-Studie von HY-133, einem rekombinanten Phagen-Lysin zur schnellen Dekolonisierung von Staphylococcus aureus aus Nasenhabitaten)“ (HY-133-Phase-I) (TTU 08.921_00)
T. Eigentler, A. Peschel, K. Becker
10/2021 – 06/2026
The joined project aims to manufacture a bacteriophage endolysin (HY-133, HYpharm) investigational medicinal product (IMP), perform stability investigations and a Phase Ia clinical trial and to study the effects of HY-133 on the nasal microbiome in study subjects.
